Loading...
•
Sep 30, 2021
McKesson Q2 2022 Earnings Report
McKesson reported strong second-quarter results, with revenue up 9% and adjusted EPS increasing by 28%.
Key Takeaways
McKesson Corporation reported strong second-quarter results for the period ended September 30, 2021. Total revenues increased by 9% driven by growth in the U.S. Pharmaceutical segment. Adjusted Earnings per Diluted Share increased by 28%. The company raised its fiscal 2022 Adjusted Earnings per Diluted Share guidance range to $21.95 to $22.55.
Total revenues increased 9% year-over-year to $66.6 billion.
Earnings per diluted share from continuing operations decreased to $1.71.
Adjusted Earnings per Diluted Share increased 28% year-over-year to $6.15.
Increased fiscal 2022 Adjusted Earnings per Diluted Share guidance range to $21.95 to $22.55.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson raised fiscal 2022 Adjusted Earnings per Diluted Share guidance to $21.95 to $22.55 from the previous range of $19.80 to $20.40 to reflect strong operating performance and increased contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs.
Positive Outlook
- $1.30 to $1.80 related to the U.S. government’s COVID-19 vaccine distribution, kitting, and storage programs
- $0.50 to $0.75 related to COVID-19 tests and impairments for personal protective equipment and related products
- $0.49 related to year-to-date gains or losses associated with McKesson Ventures’ equity investments
- Strong operating performance
- Increased contribution from the U.S. government's COVID-19 vaccine distribution, kitting, and storage programs.
Revenue & Expenses
Visualization of income flow from segment revenue to net income